Wolfe W G, Vaughn A L, Seigler H F, Hathorn J W, Leopold K A, Duhaylongsod F G
Department of Surgery, Duke University Medical Center, Durham, NC 27710.
J Thorac Cardiovasc Surg. 1993 Apr;105(4):749-55; discussion 755-6.
Since 1985, 229 cases of carcinoma of the esophagus have been considered for entry into a protocol with the use of preoperative chemotherapy and radiation therapy followed by surgical intervention as the primary element of treatment. One hundred sixty-five patients (93 with adenocarcinoma and 72 with squamous cell carcinoma) had esophagogastrectomy. The 5-year survival of the protocol patients who underwent resection was 25% for both groups--squamous cell carcinoma and adenocarcinoma. Of the protocol patients with squamous cell carcinoma who underwent resection, 40% had a sterilized specimen, whereas of those with adenocarcinoma, 20% had a sterilized specimen. If the patient had a sterilized specimen, the 5-year survival was approximately 60% for adenocarcinoma and 40% for squamous cell carcinoma. Those patients with adenocarcinoma and Barrett's esophagus had a 5-year survival of 55%. Of the patients who underwent only esophagectomy and esophagogastrectomy and had not been entered into the protocol, none lived beyond 3 years. The operative mortality rate for those who had esophagogastrectomy was 5%. Sixty-four patients completed the radiation therapy and chemotherapy but did not undergo surgical procedures because of progressive disease or refusal. Of those patients who completed chemotherapy and radiation therapy without surgical intervention, 5-year survival was 18% in patients with squamous cell carcinoma, whereas no patients with adenocarcinoma survived beyond 3 years. The finding of a sterilized specimen after esophagectomy is a favorable prognostic factor in patients with adenocarcinoma or squamous cell carcinoma. The finding that patients with Barrett's esophagus and adenocarcinoma have an improved chance for survival is perhaps related to an earlier diagnosis. It is clear that some patients with squamous cell carcinoma who did not undergo surgical procedures did have a sterilized specimen, because the survival in this group approached 20% at 5 years.
自1985年以来,229例食管癌患者被纳入一项治疗方案,该方案采用术前化疗和放疗,随后进行手术干预作为主要治疗手段。165例患者(93例腺癌和72例鳞状细胞癌)接受了食管胃切除术。接受切除的方案患者中,鳞状细胞癌和腺癌两组的5年生存率均为25%。在接受切除的方案鳞状细胞癌患者中,40%的标本无癌细胞残留,而腺癌患者中这一比例为20%。如果患者的标本无癌细胞残留,腺癌的5年生存率约为60%,鳞状细胞癌为40%。腺癌合并巴雷特食管的患者5年生存率为55%。仅接受食管切除术和食管胃切除术且未纳入该方案的患者,无一例存活超过3年。接受食管胃切除术患者的手术死亡率为5%。64例患者完成了放疗和化疗,但因疾病进展或拒绝而未接受手术。在未接受手术干预而完成化疗和放疗的患者中,鳞状细胞癌患者的5年生存率为18%,而腺癌患者无一例存活超过3年。食管切除术后标本无癌细胞残留是腺癌或鳞状细胞癌患者的一个有利预后因素。巴雷特食管合并腺癌的患者生存机会增加这一发现可能与早期诊断有关。显然,一些未接受手术的鳞状细胞癌患者确实有标本无癌细胞残留,因为该组患者5年生存率接近20%。